Masimo Co. (NASDAQ:MASI) Shares Sold by Amalgamated Bank

Amalgamated Bank cut its stake in shares of Masimo Co. (NASDAQ:MASI) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,390 shares of the medical equipment provider’s stock after selling 1,535 shares during the quarter. Amalgamated Bank owned approximately 0.06% of Masimo worth $3,562,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Byrne Asset Management LLC acquired a new position in Masimo during the 4th quarter worth approximately $28,000. Massmutual Trust Co. FSB ADV increased its holdings in Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Masimo in the fourth quarter valued at $36,000. NBC Securities Inc. acquired a new stake in Masimo in the third quarter valued at $34,000. Finally, Harvest Fund Management Co. Ltd lifted its holdings in Masimo by 2,888.9% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 538 shares of the medical equipment provider’s stock worth $62,000 after buying an additional 520 shares during the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $124.16 on Friday. Masimo Co. has a one year low of $75.22 and a one year high of $176.29. The stock has a market capitalization of $6.57 billion, a price-to-earnings ratio of 82.23 and a beta of 0.99. The company has a 50-day simple moving average of $136.10 and a 200-day simple moving average of $119.62. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The firm had revenue of $492.80 million during the quarter, compared to the consensus estimate of $487.70 million. During the same period in the prior year, the business earned $0.87 EPS. The firm’s revenue was down 12.8% compared to the same quarter last year. On average, analysts predict that Masimo Co. will post 3.51 EPS for the current year.

Insider Transactions at Masimo

In other news, Director Craig B. Reynolds sold 40,000 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the transaction, the director now directly owns 7,406 shares in the company, valued at $1,008,475.02. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 9.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MASI shares. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday. Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $148.00 to $170.00 in a research report on Monday, April 15th. Piper Sandler increased their target price on shares of Masimo from $117.00 to $126.00 and gave the company a “neutral” rating in a research report on Wednesday. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $117.00 to $160.00 in a research report on Monday, March 25th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $121.00 price objective (up previously from $107.00) on shares of Masimo in a report on Tuesday, January 30th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $138.71.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.